Abstract
Many disturbances in the normal function of endoplasmic reticulum (ER) cause accumulation of unfolded proteins in the lumen of ER, triggering an evolutionary conserved response, termed the unfolded protein response (UPR). The UPR is the mechanism enabling cells to cope with unfolded proteins, accumulated in ER lumen after the cell has been exposed to various unfavorable conditions. The UPR process has strong prosurvival implications, but switches towards apoptotic cell death when the stress becomes severe and unsolvable. The hallmark of the cytoprotective branch of UPR is stimulation of the expression of ER chaperones, of which ORP150 has gained a great deal of attention. ORP150 has been identified as being overexpressed in the pathology of many diseases and is involved in the cellular response to environmental stress. Although some fragmentary results concerning ORP150 molecular activity have been presented, its exact mode of action still remains unclear. In this paper we focused on the role of ORP150 in the pathogenesis of the main types of ER stress-related diseases: diabetes, neurodegenerative diseases, cardiovascular diseases and cancer.
Keywords: ORP150, ER stress, unfolded protein response, diabetes, neurodegenerative diseases, cardiovascular diseases, cancer
Current Pharmaceutical Design
Title:Molecular Chaperone ORP150 in ER Stress–related Diseases
Volume: 19 Issue: 15
Author(s): Magdalena Kusaczuk and Marzanna Cechowska-Pasko
Affiliation:
Keywords: ORP150, ER stress, unfolded protein response, diabetes, neurodegenerative diseases, cardiovascular diseases, cancer
Abstract: Many disturbances in the normal function of endoplasmic reticulum (ER) cause accumulation of unfolded proteins in the lumen of ER, triggering an evolutionary conserved response, termed the unfolded protein response (UPR). The UPR is the mechanism enabling cells to cope with unfolded proteins, accumulated in ER lumen after the cell has been exposed to various unfavorable conditions. The UPR process has strong prosurvival implications, but switches towards apoptotic cell death when the stress becomes severe and unsolvable. The hallmark of the cytoprotective branch of UPR is stimulation of the expression of ER chaperones, of which ORP150 has gained a great deal of attention. ORP150 has been identified as being overexpressed in the pathology of many diseases and is involved in the cellular response to environmental stress. Although some fragmentary results concerning ORP150 molecular activity have been presented, its exact mode of action still remains unclear. In this paper we focused on the role of ORP150 in the pathogenesis of the main types of ER stress-related diseases: diabetes, neurodegenerative diseases, cardiovascular diseases and cancer.
Export Options
About this article
Cite this article as:
Kusaczuk Magdalena and Cechowska-Pasko Marzanna, Molecular Chaperone ORP150 in ER Stress–related Diseases, Current Pharmaceutical Design 2013; 19 (15) . https://dx.doi.org/10.2174/1381612811319150016
DOI https://dx.doi.org/10.2174/1381612811319150016 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Extracellular Matrix and Integrin Interactions on Airway Smooth Muscle Phenotype and Function: It Takes Two to Tango!
Current Respiratory Medicine Reviews Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Targeting Bacterial Secretion Systems: Benefits of Disarmament in the Microcosm
Infectious Disorders - Drug Targets Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer
Current Immunology Reviews (Discontinued) Nuclear Medicine: from Photons to Physiology
Current Pharmaceutical Design Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?
Current Cancer Drug Targets Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews Potential Applications of FDG-PET/CT in COPD: A Review of the Literature
Current Molecular Imaging (Discontinued) Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Current Pharmaceutical Design RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy A Pan-Cancer Review of <i>ALK</i> Mutations: Implications for Carcinogenesis and Therapy
Current Cancer Drug Targets Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Current Drug Targets Discovery and Development of Natural Products and their Derivatives as Photosensitizers for Photodynamic Therapy
Current Medicinal Chemistry Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods
Current Medicinal Chemistry - Anti-Cancer Agents The Modulation of Pain by Metabotropic Glutamate Receptors 7 and 8 in the Dorsal Striatum
Current Neuropharmacology